Bellerophon: Jumps after therapy used in first COVID-19 patient

Bellerophon Therapeutics

30/03/2020 14:42

** Shares of Bellerophon Therapeutics  BLPH.O  jump 46% to
$18.76 
    ** Co said on Monday it used its inhaled nitric oxide
therapy, INOpulse, to treat a patient with novel coronavirus
disease(COVID-19) for the first time 
    ** Previous studies show nitric oxide could help treat
severe acute respiratory syndrome-related coronavirus and
prevent disease from progressing by inhibiting viral replication
    ** INOpulse is designed to treat people in the outpatient
setting, which could alleviate mounting impact on hospitals and
intensive care units - co
    ** Last week, FDA allowed emergency use of INOpulse to treat
COVID-19 
    ** Up to Friday's close, BLPH had more than doubled YTD

 (Reporting by Vishwadha Chander in Bengaluru)
 ((vishwadha.chander@thomsonreuters.com))